País: Canadá
Língua: inglês
Origem: Health Canada
ATORVASTATIN (ATORVASTATIN CALCIUM)
PHARMASCIENCE INC
C10AA05
ATORVASTATIN
80MG
TABLET
ATORVASTATIN (ATORVASTATIN CALCIUM) 80MG
ORAL
15G/50G
Prescription
HMG-COA REDUCTASE INHIBITORS
Active ingredient group (AIG) number: 0133055004; AHFS:
APPROVED
2018-06-08
_pms-ATORVASTATIN (atorvastatin calcium) _ _Page 1 of 63 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR PMS-ATORVASTATIN Atorvastatin Calcium Tablets Tablet, 10 mg, 20 mg, 40 mg and 80 mg atorvastatin (as atorvastatin calcium trihydrate), Oral USP Lipid Metabolism Regulator PHARMASCIENCE INC. 6111 Royalmount Ave., Suite 100 Montréal, Québec H4P 2T4 www.pharmascience.com Date of Initial Authorization JUN 08, 2018 Date of Revision: MAR 25, 2022 Submission Control Number: 260400 _pms-ATORVASTATIN (atorvastatin calcium) _ _Page 2 of 63 _ RECENT MAJOR LABEL CHANGES 2 CONTRAINDICATIONS 10/2021 7 WARNINGS AND PRECAUTIONS, Musculoskeletal 03/2022 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES............................................................................................. 2 TABLE OF CONTENTS ............................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ...................................................................... 4 1 INDICATIONS ..................................................................................................................... 4 1.1 Pediatrics ............................................................................................................... 4 1.2 Geriatrics................................................................................................................ 5 2 CONTRAINDICATIONS........................................................................................................ 5 4 DOSAGE AND ADMINISTRATION ....................................................................................... 5 4.1 Dosing Considerations ............................................................................................ 5 4.2 Recommended Dose and Dosage Adjustment.......................................................... 6 4.4 Administration.......................... Leia o documento completo